Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate.
暂无分享,去创建一个
[1] J. McKenney,et al. Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[2] Y. De Launoit,et al. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone , 2016, Oncotarget.
[3] J. Korbel,et al. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients , 2016, BMC Cancer.
[4] N. Bhoo-Pathy,et al. 1023 Prostate cancer in multi-ethnic Asian men , 2015 .
[5] S. Serrano,et al. Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels , 2015, The Prostate.
[6] S. Hilsenbeck,et al. Expression of ERG protein in prostate cancer: variability and biological correlates. , 2015, Endocrine-related cancer.
[7] S. Srivastava,et al. ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. , 2015, Molecular and clinical oncology.
[8] J. Oxley,et al. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. , 2014, American journal of clinical pathology.
[9] Huiqing Yuan,et al. ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients , 2014, PloS one.
[10] M. Nykter,et al. Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[11] S. Srivastava,et al. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India , 2013, Journal of Cancer.
[12] A. Hurtado-coll,et al. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause‐specific mortality , 2013, The Prostate.
[13] Yong-jie Lu,et al. Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. , 2013, American journal of cancer research.
[14] M. Rubin,et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer , 2013, Prostate Cancer and Prostatic Disease.
[15] S. Srivastava,et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.
[16] J. Suh,et al. ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients , 2012, Korean journal of pathology.
[17] Jennifer R. Rider,et al. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[18] Katelyn Powell,et al. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. , 2012, Journal of cancer science & therapy.
[19] G. Jenster,et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer , 2012, Modern Pathology.
[20] J. Trapman,et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice , 2011, Modern Pathology.
[21] J. Hicks,et al. Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.
[22] A. Paetau,et al. ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma , 2011, The American journal of surgical pathology.
[23] K. Moon,et al. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. , 2010, Urology.
[24] Y. Miyagi,et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples , 2010, Modern Pathology.
[25] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[26] D. Berney,et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.
[27] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[28] Matthew R Cooperberg,et al. Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[30] R. Shah,et al. CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .
[31] K. Cooney,et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study , 2008, Journal of Human Genetics.
[32] J. Trachtenberg,et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.
[33] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[34] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[35] M. Rubin,et al. TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.
[36] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.
[37] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[38] A. Chokkalingam,et al. Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.
[39] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[40] H. Sim,et al. Changing demography of prostate cancer in Asia. , 2005, European journal of cancer.
[41] Lang Li,et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.
[42] Ruth Etzioni,et al. Androgen receptor polymorphisms and the incidence of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[43] Å. Borg,et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk , 1999, British Journal of Cancer.
[44] L. Liotta,et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.
[45] D. Bostwick,et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.
[46] D. Grignon,et al. Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.
[47] P. Scardino,et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. , 1991, The Journal of urology.